Disturbances of endometrial bleeding with hormone replacement therapy

A M Thomas, Arul Thomas, Martha Hickey, M Hickey, Ian S. Fraser, I S Fraser
Human Reproduction · 2000 · vol. 15(suppl 3) , pp. 7–17 · doi:10.1093/humrep/15.suppl_3.7 · PMID:11041216 · W2169480780
Review OA: closed CC0 ⤵ 9 in-corpus citations
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-07 ⓘ

This paper discusses breakthrough bleeding in postmenopausal women using hormone replacement therapy, its potential mechanisms, diagnostic challenges, and impact on HRT acceptability.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Breakthrough bleeding is a common problem in postmenopausal women taking hormone replacement therapy (HRT) and is often the single most important factor deterring women from continuing to use HRT, or from starting it in the first place. The mechanisms which underlie this unscheduled bleeding are poorly understood. The benefits of HRT in terms of longevity and quality of life are becoming increasingly apparent, and a greater understanding of why this bleeding occurs and how we can prevent or treat it, will undoubtedly enable more women to reap the potential considerable benefits of long-term oestrogen and progestogen replacement. What sets postmenopausal women apart from their counterparts in the mid-reproductive years is the increased likelihood of endometrial adenocarcinoma in which unscheduled bleeding is the presenting symptom. Therefore, spontaneous postmenopausal bleeding must always be appropriately evaluated. Hence, the occurrence of unscheduled bleeding with HRT may provide a dilemma with diagnosis as well as a challenge to acceptability. Combined HRT regimens tend to be predominantly progestogenic, and there is increasing evidence to suggest that some of the vascular changes seen in women taking long-term, low-dose progestogen-only contraceptives may also occur in women taking HRT.

My notes (saved in your browser only)

MeSH descriptors

Hormone Replacement Therapy Uterine Hemorrhage Adenocarcinoma Adenocarcinoma Endometrial Neoplasms Endometrial Neoplasms Endometrium Endometrium Endometrium Estrogen Replacement Therapy Estrogen Replacement Therapy Estrogens Estrogens Estrogens Female Hormone Replacement Therapy Humans Postmenopause Progestins Progestins

Citation neighborhood (2-hop)

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. Outer rings show 2-hop neighbours — papers reached through the immediate citers/citees. [ collapse to 1-hop ]

References (42)

Cited by (8)

Source provenance

openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-10-08T20:59:38.477535+00:00
unpaywall
last seen: 2026-10-15T06:24:24.424788+00:00
License: CC0 · commercial use OK